CA
NZ
UK
AU
IND
US
Liquidia's October 13, 2026 release said it would not appeal the September 30 ruling and had filed a label supplement removing the indication for pulmonary hypertension associated with interstitial lung disease from Yutrepia. The settlement closes six lawsuits, with dismissals with prejudice after the …
No company announcement dated October 14, 2026 was found to explain Lilly's 3.45% advance, which appears to extend the response to its August 5 results. Revenue reached USD 22.97 billion, up 48%, with the incretin portfolio a major contributor. Mounjaro, tirzepatide for type 2 …
No Revolution Medicines announcement dated October 14, 2026 was identified to explain the 3.85% gain. R&D spending rose to USD 394.9 million from USD 224.1 million, while general and administrative costs increased to USD 110.2 million from USD 40.6 million. A warrant-related charge reflects …
No company announcement dated October 14, 2026 was found, so CAI's 4.03% rise followed the August 5 second-quarter update rather than a fresh disclosed event. Caris reported approximately 59,200 clinical cases, up about 18%, and more than 114,000 whole-exome and whole-transcriptome tests. Gross margin …
No company announcement dated October 14, 2026 was found, so Zura's 3.78% gain appears to follow the August 11 second-quarter report. The company is developing tibulizumab, an antibody targeting BAFF and IL-17 pathways, across two Phase 2 trials. General and administrative expense declined to …
No Axsome announcement dated October 14, 2026 was identified, so its 3.95% rise followed the August 10 second-quarter report. Auvelity net sales increased to USD 180.3 million from USD 119.6 million. Sunosi generated USD 35.8 million, including USD 1.5 million of royalties and USD …
No AngioDynamics announcement dated October 14, 2026 was found, so the 3.35% gain followed the October 8 fiscal first-quarter report. The company said Auryon atherectomy sales rose 14.7% to USD 18.9 million, NanoKnife irreversible-electroporation revenue climbed 29.0% to USD 8.3 million and AlphaVac mechanical …
In its October 13, 2026 announcement, Liquidia said it would not appeal the September 30 decision and had submitted a label supplement removing the pulmonary-hypertension-associated-with-interstitial-lung-disease indication from Yutrepia. The agreement settles six lawsuits, with dismissals with prejudice following the initial payment. Yutrepia will remain …
Verastem scheduled its webcast for 8:00 a.m. ET on Wednesday, October 14, 2026, to discuss TARGET-D programme data following a clinical update in June. The timing coincided with an 11.21% gain, but the specific efficacy figures were not verified for this article, so the …
No company announcement dated October 14, 2026 was found, and the 5.59% gain occurred on relatively light volume. Published market data put LENZ’s market capitalisation near USD 113 million, below the USD 220.0 million in cash and marketable securities held at June 30. A …
Please wait processing your request...